[Microangiopathic hemolytic anemia].
D000743:Anemia, Hemolytic / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology; D001778:Blood Coagulation Disorders / Q000150:complications / Q000188:drug therapy; D003093:Colitis, Ulcerative / Q000150:complications; D004461:Eclampsia / Q000150:complications; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006084:Graft Rejection; D006349:Heart Valve Diseases / Q000150:complications; D006350:Heart Valve Prosthesis / Q000009:adverse effects; D006463:Hemolytic-Uremic Syndrome / Q000150:complications; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D006974:Hypertension, Malignant / Q000150:complications; D016030:Kidney Transplantation; D008833:Microcirculation; D009369:Neoplasms / Q000150:complications; D011247:Pregnancy; D014184:Transplantation, Homologous
D005343:Fibrinolytic Agents; D006493:Heparin
Die mikroangiopathisch-hämolytische Anämie.